Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial

被引：0
|
作者：
Wang, S. [1 ]
Hong, R. [2 ]
Xu, F. [2 ]
Xia, W. [2 ]
Teng, Y. [3 ]
Ouyang, Q. [4 ]
Yuan, Z. [2 ]
Jiang, K. [2 ]
Lin, Y. [5 ]
Liu, X. [6 ]
Chen, Q. [7 ]
Wu, X. [8 ]
Shi, Y. [2 ]
Huang, J. [2 ]
An, X. [2 ]
Xue, C. [2 ]
Bi, X. [2 ]
Zheng, Q. [2 ]
Chen, M. [2 ]
Li, H. [9 ]
机构：
[1] Sun Yat Sen Univ Canc Ctr, Med Oncol, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ Canc Ctr, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[3] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Liaoning, Peoples R China
[4] Hunan Canc Hosp, Dept Breast Canc Med Oncol, Changsha, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast Surg, Guangzhou, Peoples R China
[6] Ningxia Med Univ, Gen Hosp, Dept Med Oncol, Yinchuan, Ningxia, Peoples R China
[7] Guangdong Prov Chinese Med Hosp, Dept Breast, Guangzhou, Peoples R China
[8] Hubei Canc Hosp, Dept Breast, Wuhan, Peoples R China
[9] Sichuan Canc Hosp, Dept Breast Surg, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.319
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
371P
引用
收藏
页码：S374 / S374
页数：1
相关论文
共 50 条
  • [31] Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
    Minetta C. Liu
    Javier Cortés
    Joyce O’Shaughnessy
    Cancer and Metastasis Reviews, 2016, 35 : 323 - 332
  • [32] Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
    Liu, Minetta C.
    Cortes, Javier
    O'Shaughnessy, Joyce
    CANCER AND METASTASIS REVIEWS, 2016, 35 (02) : 323 - 332
  • [33] Association of Endocrine Therapy with Survival for Patients with Small, Hormone Receptor-Positive, HER2-Negative, Breast Cancer
    Ma, S. J.
    Oladeru, O. T.
    Sood, A. J.
    Mikucki, M.
    Farrugia, M. K.
    Singh, A. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E74 - E74
  • [34] Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
    Tolaney, Sara M.
    Beeram, Muralidhar
    Beck, J. Thaddeus
    Conlin, Alison
    Dees, E. Claire
    Puhalla, Shannon L.
    Rexer, Brent N.
    Burris, Howard A., III
    Jhaveri, Komal
    Helsten, Teresa
    Becerra, Carlos
    Kalinsky, Kevin
    Moore, Kathleen N.
    Manuel, Allison M.
    Lithio, Andrew
    Price, Gregory L.
    Chapman, Sonya C.
    Litchfield, Lacey M.
    Goetz, Matthew P.
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [35] The association of hormone receptor expression level and clinical efficacy of CDK4/6 inhibitor in hormone receptor-positive, HER2-negative metastatic breast cancer
    Bao, Kelvin K. H.
    Wong, Carol H. Y.
    Yung, Jackie
    Tam, Venus
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    Yiu, Harry H. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Hugo Herrscher
    Michel Velten
    Julie Leblanc
    Michal Kalish-Weindling
    Cathie Fischbach
    Delphine Exinger
    Xavier Pivot
    Thierry Petit
    Breast Cancer Research and Treatment, 2020, 179 : 371 - 376
  • [37] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Herrscher, Hugo
    Velten, Michel
    Leblanc, Julie
    Kalish-Weindling, Michal
    Fischbach, Cathie
    Exinger, Delphine
    Pivot, Xavier
    Petit, Thierry
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (02) : 371 - 376
  • [38] Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN)
    Rimawi, Mothaffar F.
    Poole, Christopher John
    Ferrero, Jean-Marc
    Rodriguez, Juan R. De la Haba
    Mitchell, Lada
    Pelizon, Christina H.
    Arpino, Grazia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer
    Moy, Beverly
    Neven, Patrick
    Lebrun, Fabienne
    Bellet, Meritxell
    Xu, Binghe
    Sarosiek, Tomasz
    Chow, Louis
    Goss, Paul
    Zacharchuk, Charles
    Leip, Eric
    Turnbull, Kathleen
    Bardy-Bouxin, Nathalie
    Duvillie, Ladan
    Lang, Istvan
    ONCOLOGIST, 2014, 19 (04): : 348 - 349
  • [40] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1176 - 1177
12345